AC
BNGO icon

Armistice Capital’s Bionano Genomics BNGO Stock Holding History

Armistice Capital’s Portfolio BNGO Stock Details BNGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-27,967
Closed -$1.14M – 266
2024
Q2 		$1.14M Buy
+27,967
New +$1.54M 0.01% 158

Other funds holding BNGO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
CAM
Carret Asset Management New York $1.02B AUM 26.95% 1-Year Est. Return

Armistice Capital's BNGO Position: Q3 2024 in Review

Armistice Capital sold out of Bionano Genomics (BNGO) in Q3 2024, closing a stake of 27,967 shares — an estimated $1.14M sold.

Armistice Capital first reported a position in BNGO in Q2 2024 and held it in 1 quarter. The position peaked at $1.14M in Q2 2024. 47 funds tracked by Wall St. Rank hold BNGO as of Q3 2024.

  • Armistice Capital reported no remaining Bionano Genomics position as of Q3 2024 after selling out during the quarter.
  • Armistice Capital sold 27,967 Bionano Genomics shares in Q3 2024, an estimated $1.14M.
  • Armistice Capital first reported a position in Bionano Genomics in Q2 2024 and held it in 1 quarter.
  • Armistice Capital's Bionano Genomics position peaked at $1.14M in Q2 2024.
  • 47 funds tracked by Wall St. Rank held Bionano Genomics as of Q3 2024.

Based on Armistice Capital's 13F filing for Q3 2024, filed 14 Nov 2024.